Internal Reference Number: FOI_6404
Date Request Received: 17/12/2021 00:00:00
Date Request Replied To: 19/01/2022 00:00:00
This response was sent via: By Email
Request Summary: Biologic medications in gastroenterology
Request Category: Companies
| Question Number 1: How many patients were treated in November 2021 (or latest available month) by the gastroenterology department with the following drugs: • Adalimumab (any brand or biosimilar) • Infliximab (any brand or biosimilar) • Ustekinumab (Stelara) • Vedolizumab (Entyvio) • Tofacitinib (Xeljanz) • Filgotinib (Jyseleca) | |
| Answer To Question 1: Adalimumab 69 Infliximab 69 Ustekinumab 39 Vedolizumab 18 Tofacitinib less than 5 Filgotinib 0 | |
| Question Number 2: How many patients were treated in November 2021 (or latest available month) for Crohn’s Disease ONLY with the following drugs: • Adalimumab (any brand or biosimilar) • Infliximab (any brand or biosimilar) • Ustekinumab (Stelara) • Vedolizumab (Entyvio) | |
| Answer To Question 2: Adalimumab 73 Infliximab 64 Ustekinumab 33 Vedolizumab 12 | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of ¾¨Ó㴫ý Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
